Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best NASDAQ growth stocks to buy for the next 2 years.
Alnylam Pharmaceuticals Inc. (ALNY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Orbis Investment Management William B. Gray | 1,618,219 | $643,484,786 | -18% | 2.7% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 1,132,560 | $450,362,484 | +27% | 0.88% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,127,162 | $448,215,969 | -17% | 0.26% |
| 4. | AQR Capital Management Cliff Asness | 919,959 | $365,821,629 | +24% | 0.19% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 549,922 | $218,676,482 | +9% | 0.2% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.67 | 4 | $1,210.68 | 36 | 2024-10-17 | Filing | |
| $286.00 | 32 | $9,152.00 | 32 | 2024-08-29 | Filing | |
| $71.87 | 297,501 | $21,381,396.87 | 10,554,134 | 2017-05-31 | Filing | |
| $65.35 | 11,500 | $751,502.00 | 11,500 | 2017-05-30 | Filing | |
| $37.00 | 27,900 | $1,032,327.90 | 27,900 | 2016-10-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $310.08 | 2,242 | $695,201.15 | 24,848 | 2026-02-13 | Filing | |
| $310.08 | 6,958 | $2,157,542.21 | 85,662 | 2026-02-13 | Filing | |
| $310.08 | 1,959 | $607,448.29 | 31,769 | 2026-02-13 | Filing | |
| $331.96 | 2,041 | $677,531.58 | 21,264 | 2026-02-17 | Filing | |
| $310.08 | 1,959 | $607,448.29 | 23,305 | 2026-02-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,301,772 | $6,482,389,029 | 0.88% | |
| 2. | 15,902,149 | $6,323,489,463 | 0.32% | |
| 3. | 13,553,932 | $5,389,721,059 | 0.08% | |
| 4. | 10,400,874 | $4,135,907,609 | 0.07% | |
| 5. | 6,779,708 | $2,695,945,984 | 0.5% |
News See All
10 Best NASDAQ Growth Stocks to Buy for the Next 2 Years
On February 19, Tom Lee of Fundstrat and BitMine joined 'Closing Bell' on CNBC to talk about the state of the markets.
Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the best money-making stocks to buy right now. On February 13, Morgan Stanley trimmed the price target on Alnylam Pharmaceuticals, Inc.
11 Best Money-Making Stocks to Buy Right Now
In an environment marked by shifting rate expectations and growth volatility, investors remain focused on identifying companies capable of delivering sustainable earnings expansion.
Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now?
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best upside stocks to invest in right now.
13 Best Upside Stocks to Invest In Right Now
On February 10, Sam Stovall, chief investment strategist at CFRA, and Tim Seymour, founder of Seymour Asset Management, appeared on CNBC’s 'Closing Bell Overtime' to discuss how investors are currently...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2025 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2025 Earnings Call Transcript February 12, 2026Alnylam Pharmaceuticals, Inc. misses on earnings expectations.
Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the best healthcare stocks to buy for 2026. On January 20, RBC Capital reiterated an Outperform rating on Alnylam Pharmaceuticals, Inc.
12 Best Healthcare Stocks to Buy for 2026
Artificial Intelligence has been the catalyst behind the blockbuster rally in equity markets over the past two years.
Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy
On January 11, Alnylam Pharmaceuticals, Inc.
Hedge Fund Resource Center